Key facts
- ChromaTan’s last known valuation is $11.0M (Jan 2021).
- It has raised $12.4M across 1 recorded rounds; the latest was Seed Round ($2.7M) in May 2019.
- Notable investors include MassChallenge, National Institutes of Health, Ben Franklin Technology Partners of Southeastern Pennsylvania, Lateral Capital Management, Ben Franklin Technology Partners of Central and Northern Pennsylvania — 24 tracked in total.
- ChromaTan has filed 1 Form D with the SEC, most recently Jun 2019 ($2.7M sold to 25 investors).
- Status: Privately Held (backing).
Investors
24+- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for ChromaTan
Funding rounds
1 roundsAbout ChromaTan
Developer of a biologics purification technology designed for single-use and continuous biomanufacturing. The company's technology offers a continuous countercurrent tangential chromatography that enables continuous, single-use, and column-free purification of biologics, enabling healthcare professionals to have a cost-saving and scalable alternative to column chromatography.
- Sector
- Healthcare
- HQ
- Lower Gwynedd, PA, United States
- Founded
- 2009
- Employees
- 15
- Website
- chromatan.com/
- Ownership
- Privately Held (backing)
ChromaTan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ChromaTan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ChromaTan in its N-PORT filings yet. We sweep new filings monthly.